Ｉｎｄｏｍｅｔａｃｉｎ　ｆａｒｎｅｓｉｌのヒトＢ細胞免疫グロブリン産生に対する抑制作用　　特にｂｕｃｉｌｌａｍｉｎｅ・注射金剤との相互作用

• 広畑 俊成

  帝京大学医学部内科学教室

• 柳田 たみ子

  帝京大学医学部内科学教室

書誌事項

タイトル別名

• Inhibition of human B cell activation by indometacin farnesil: Its additive effects to the inhibitory influences of bucillamine or gold compounds.
• <I>Its additive effects to the inhibitory influences of bucillamine or gold compounds</I>
• ―特にbucillamine・注射金剤との相互作用―

抄録

Indometacin farnesil (IMF) is a prodrug of indomethacin (IND) designed to reduce the occurrence of side-effects by esterification of the carboxyl group on IND with farnesol (FAR) . Previous studies have shown that IMF has characteristics of disease modifying anti-rheumatic drug in that it has a component of slow acting effect in treatment of rheumatoid arthritis patients. We therefore examined the effects of IMF on human B cells. Ig production was induced from highly purified B cells obtained from healthy donors by stimulation with Staphylococcus aureus Cowan I (SA) plus IL-2. At pharmacologically attainable concentrations, IMF, but not IND, suppressed the production of IgM and IgG. Of note, IMF, but not IND, showed additive suppressive effects on the B cell Ig production in the presence of either intramolecular disulfide form of bucillamine (SA-981) or gold sodium thiomalate. FAR showed similar suppressive effects on B cells to those of IMF.<BR>These results indicate that IMF suppresses the human B cell functions by a different mechanism from that of bucillamine or gold sodium thiomalate. Thus, the data suggest that IMF may enhance the antirheumatic effects of bucillamine or gold sodium thiomalate.

収録刊行物

• 炎症

  炎症 17 (6), 565-571, 1997

  日本炎症・再生医学会

キーワード

• <I>B cell</I>
• <I>Ig production</I>
• <I>bucillamine</I>
• <I>gold sodium thiomalate</I>
• <I>farnesol</I>

詳細情報

• CRID: 1390001204785944832
• NII論文ID: 130003709524
• DOI: 10.2492/jsir1981.17.565
• ISSN: 18844006
• ISSN: 03894290
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可